Roles for Treg Expansion and HMGB1 Signaling through the TLR1-2-6 Axis in Determining the Magnitude of the Antigen-Specific Immune Response to MVA85A

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  Matsumiya, Magali ^a   Stylianou, Elena ^a   Griffiths, Kristin ^a   Lang, Zoe ^a   Meyer, Joel ^a   Harris, Stephanie A ^a   Rowland, Rosalind ^a   Minassian, Angela M ^a   Pathan, Ansar A ^a,b   Fletcher, Helen ^a   McShane, Helen ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b BRUNEL UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL VACCINE; CD14 ANTIGEN; CD4 ANTIGEN; CXCL2 CHEMOKINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; HIGH MOBILITY GROUP B1 PROTEIN; INTERLEUKIN 2 RECEPTOR ALPHA; MODIFIED VACCINIA VIRUS ANKARA 85A VACCINE; NEUTRALIZING ANTIBODY; PATTERN RECOGNITION RECEPTOR; RECEPTOR ANTIBODY; TOLL LIKE RECEPTOR 1; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 2 ANTIBODY; TOLL LIKE RECEPTOR 6; TOLL LIKE RECEPTOR ADAPTOR MOLECULE 2; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN SPECIFICITY; ARTICLE; CD4+ CD25+ FOXP3+ T LYMPHOCYTE; CELL EXPANSION; CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RESPONSE; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; INNATE IMMUNITY; MOUSE; NONHUMAN; PROTEIN SECRETION; REGULATORY T LYMPHOCYTE; SIGNAL TRANSDUCTION; SUPERNATANT; T LYMPHOCYTE; TUBERCULOSIS;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADOLESCENT; ADULT; ANIMALS; ANTIGENS, CD14; CLUSTER ANALYSIS; EPITOPES, T-LYMPHOCYTE; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HMGB1 PROTEIN; HUMANS; IMMUNITY, INNATE; MICE; MIDDLE AGED; SIGNAL TRANSDUCTION; T-LYMPHOCYTES, REGULATORY; TOLL-LIKE RECEPTOR 1; TOLL-LIKE RECEPTOR 2; TOLL-LIKE RECEPTOR 6; TOLL-LIKE RECEPTORS; TUBERCULOSIS VACCINES; VACCINATION; YOUNG ADULT;

MUS; VACCINIA VIRUS ANKARA;

EID: 84879742350     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0067922     Document Type: Article

References (61)

1. WHO (2012) Global tuberculosis report 2012. Elsevier.
2. Rodrigues LC, Diwan VK, Wheeler JG, (1993) Protective effect of BCG against tuberculous meningitis and miliary tuberculosis: a meta-analysis. Int J Epidemiol 22: 1154-1158. doi:10.1093/ije/22.6.1154. PubMed: 8144299.
3. Colditz GA, Berkey CS, Mosteller F, Brewer TF, Mary E, et al. (1995) The Efficacy of Bacillus Calmette-Guérin Vaccination of Newborns and Infants in the Prevention of Tuberculosis: Meta-Analyses of the Published Literature. Pediatrics: pp. 29-35.
4. Fine PE, (1995) Variation in protection by BCG: implications of and for heterologous immunity. Lancet 346: 1339-1345. doi:10.1016/S0140-6736(95)92348-9. PubMed: 7475776.
5. Brennan MJ, Stone MR, Evans T, (2012) Yew W-W, STATE OF THE ART New Tools, Series. NUMBER. p. pp. 5 IN THE SERIES A rational vaccine pipeline for tuberculosis OF TUBERCULOSIS VACCINE CANDIDATES. 16: 1566-1573.
6. Tameris MD, Hatherill M, Landry BS, Scriba TJ, Snowden MA, et al. (2013) Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet 6736: 1-8. doi:10.1016/S0140-6736(13)60177-4. PubMed: 23391465.
7. Aagaard C, Dietrich J, Doherty M, Andersen P, (2009) TB vaccines: current status and future perspectives. Immunol Cell Biol 87: 279-286. doi:10.1038/icb.2009.14. PubMed: 19350048.
8. Von Eschen K, Morrison R, Braun M, Ofori-Anyinam O, De Kock E, et al. (2009) The candidate tuberculosis vaccine Mtb72F/AS02A: Tolerability and immunogenicity in humans. Hum Vaccin 5: 475-482. PubMed: 19587528.
9. Hoft DF, Blazevic A, Abate G, Hanekom WA, Kaplan G, et al. (2009) A New Recombinant BCG Vaccine Safely Induces Significantly Enhanced TB-specific Immunity in Human Volunteers. J Infect Dis 198: 1491-1501. doi:10.1086/592450.A.
10. Hanekom Wa, Dockrell HM, Ottenhoff THM, Doherty TM, Fletcher H, et al. (2008) Immunological outcomes of new tuberculosis vaccine trials: WHO panel recommendations. PLOS Med 5: e145. doi:10.1371/journal.pmed.0050145. PubMed: 18597551.
11. Kagina BMN, Abel B, Scriba TJ, Hughes EJ, Keyser A, et al. (2010) Specific T cell frequency and cytokine expression profile do not correlate with protection against tuberculosis after bacillus Calmette-Guérin vaccination of newborns. Am J Respir Crit Care Med 182: 1073-1079. doi:10.1164/rccm.201003-0334OC. PubMed: 20558627.
12. Szabo SJ, Kim ST, Costa GL, Zhang X, Fathman CG, et al. (2000) A novel transcription factor, T-bet, directs Th1 lineage commitment. Cell 100: 655-669. doi:10.1016/S0092-8674(00)80702-3. PubMed: 10761931.
13. Montefiori DC, Karnasuta C, Huang Y, Ahmed H, Gilbert P, et al. (2012) Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials. J Infect Dis 206: 431-441. doi:10.1093/infdis/jis367. PubMed: 22634875.
14. Goodman AG, Heinen PP, Guerra S, Vijayan A, Sorzano COS, et al. (2011) A human multi-epitope recombinant vaccinia virus as a universal T cell vaccine candidate against influenza virus. PLOS ONE 6: e25938. doi:10.1371/journal.pone.0025938. PubMed: 21998725.
15. McShane H, Pathan, A a, Sander CR, Keating SM, Gilbert SC,et al (2004) Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nat Med 10: 1240-1244. doi:10.1038/nm1128. PubMed: 15502839.
16. Sheehy SH, Duncan CJa, Elias SC, Choudhary P, Biswas S, et al. (2012) ChAd63-MVA-vectored blood-stage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humans. Molecular Therapy J American Society Of Gene Therapy 20: 2355-2368. doi:10.1038/mt.2012.223. PubMed: 23089736.
17. Krupa M, Canamero M, Gomez CE, Najera JL, Gil J, et al. (2011) Immunization with recombinant DNA and modified vaccinia virus Ankara (MVA) vectors delivering PSCA and STEAP1 antigens inhibits prostate cancer progression. Vaccine 29: 1504-1513. doi:10.1016/j.vaccine.2010.12.016. PubMed: 21182993.
18. Odunsi K, Matsuzaki J, Karbach J, Neumann A, Mhawech-Fauceglia P, et al. (2012) Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma patients. Proc Natl Acad Sci U S A 109: 5797-5802. doi:10.1073/pnas.1117208109. PubMed: 22454499.
19. Guzman E, Cubillos-Zapata C, Cottingham MG, Gilbert SC, Prentice H, et al. (2012) Modified vaccinia virus Ankara-based vaccine vectors induce apoptosis in dendritic cells draining from the skin via both the extrinsic and intrinsic caspase pathways, preventing efficient antigen presentation. J Virol 86: 5452-5466. doi:10.1128/JVI.00264-12. PubMed: 22419811.
20. Pascutti MF, Rodríguez AM, Falivene J, Giavedoni L, Drexler I, et al. (2011) Interplay between modified vaccinia virus Ankara and dendritic cells: phenotypic and functional maturation of bystander dendritic cells. J Virol 85: 5532-5545. doi:10.1128/JVI.02267-10. PubMed: 21411535.
21. Mohamed MR, McFadden G, (2009) NFkB inhibitors: strategies from poxviruses. Cell Cycle (Georgetown, Tex) 8: 3125-3132. doi:10.4161/cc.8.19.9683. PubMed: 19738427.
22. Perdiguero B, Gomez CE, Najera JL, Sorzano COS, Roger T, et al. (2012) Deletion of the Viral Anti-Apoptotic Gene F1L in the HIV/ AIDS Vaccine Candidate MVA-C Enhances Immune Responses against HIV-1 Antigens. 7. doi:10. 1371/journal.pone.0048524.
23. Delaloye J, Roger T, Steiner-Tardivel Q-G, Le Roy D, Knaup Reymond M, et al. (2009) Innate immune sensing of modified vaccinia virus Ankara (MVA) is mediated by TLR2-TLR6, MDA-5 and the NALP3 inflammasome. PLOS Pathog 5: e1000480. doi:10.1371/journal.ppat.1000480. PubMed: 19543380.
24. Nakaya H, Li S, Pulendran B, (2012). Systems vaccinology: Learn to Compute the Behavior of Vaccines Induced Immun: pp. 1-18. doi:10.1002/wsbm.163.Systems.
25. Querec TD, Akondy RS, Lee EK, Cao W, Nakaya HI, et al. (2009) Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nat Immunol 10: 116-125. doi:10.1038/ni.1688. PubMed: 19029902.
26. Scriba TJ, Tameris M, Mansoor N, Smit E, Van der Merwe L, et al. (2010) Modified vaccinia Ankara-expressing Ag85A, a novel tuberculosis vaccine, is safe in adolescents and children, and induces polyfunctional CD4+ T cells. Eur J Immunol 40: 279-290. doi:10.1002/eji.200939754. PubMed: 20017188.
27. Scriba TJ, Tameris M, Mansoor N, Smit E, Van der Merwe L, et al. (2011) Dose-finding study of the novel tuberculosis vaccine, MVA85A, in healthy BCG-vaccinated infants. J Infect Dis 203: 1832-1843. doi:10.1093/infdis/jir195. PubMed: 21606542.
28. Minassian AM, Rowland R, Beveridge NER, Poulton ID, Satti I, et al. (2011) A Phase I study evaluating the safety and immunogenicity of MVA85A, a candidate TB vaccine, in HIV-infected adults. BMJ open. p. pp. 1: e000223. doi:10.1136/bmjopen-2011-000223.
29. Sander CR, Pathan, A a, Beveridge NER, Poulton I, Minassian A,et al (2009) Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in Mycobacterium tuberculosis-infected individuals. Am J Respir Crit Care Med 179: 724-733. doi:10.1164/rccm.200809-1486OC. PubMed: 19151191.
30. Meyer J, Harris Sa, Satti I, Poulton ID, Poyntz HC, et al. (2013) Comparing the safety and immunogenicity of a candidate TB vaccine MVA85A administered by intramuscular and intradermal delivery. Vaccine 31: 1026-1033. doi:10.1016/j.vaccine.2012.12.042. PubMed: 23266342.
31. Mootha VK, Lindgren CM, Eriksson K-F, Subramanian A, Sihag S, et al. (2003) PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet 34: 267-273. doi:10.1038/ng1180. PubMed: 12808457.
32. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, et al. (2005) Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 102: 15545-15550. doi:10.1073/pnas.0506580102. PubMed: 16199517.
33. Huang DW, Sherman BT, Lempicki R a (2009) Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res 37: 1-13. doi:10.1093/nar/gkn923. PubMed: 19033363.
34. Huang DW, Sherman BT, Lempicki R a (2009) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4: 44-57. doi:10.1038/nprot.2008.211. PubMed: 19131956.
35. Guo Y, Hastie T, Tibshirani R, (2007) Regularized linear discriminant analysis and its application in microarrays. Biostatistics (Oxf, England) 8: 86-100. doi:10.1093/biostatistics/kxj035. PubMed: 16603682.
36. Pathan, A a, Minassian AM, Sander CR, Rowland R, Porter DW,et al (2012) Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adults. Vaccine, 31: 1-9. doi:10.1016/j.vaccine.2012.06.084. PubMed: 23142303.
37. Farhat K, Riekenberg S, Heine H, Debarry J, Lang R, et al. (2008) Heterodimerization of TLR2 with TLR1 or TLR6 expands the ligand spectrum but does not lead to differential signaling. J Leukoc Biol 83: 692-701. doi:10.1189/jlb.0807586. PubMed: 18056480.
38. Janssens S, Beyaert R, (2003) Role of Toll-Like Receptors in Pathogen Recognition Role of Toll-Like Receptors in Pathogen Recognition. 16. doi:10.1128/CMR.16.4.637.
39. Kazama H, Ricci J-E, Herndon JM, Hoppe G, Green DR, et al. (2008) Induction of immunological tolerance by apoptotic cells requires caspase-dependent oxidation of high-mobility group box-1 protein. Immunity 29: 21-32. doi:10.1016/j.immuni.2008.05.013. PubMed: 18631454.
40. Scaffidi P, Misteli T, Bianchi ME, (2002) Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 418: 191-195. doi:10.1038/nature00858. PubMed: 12110890.
41. Urbonaviciute V, Fürnrohr BG, Meister S, Munoz L, Heyder P, et al. (2008) Induction of inflammatory and immune responses by HMGB1-nucleosome complexes: implications for the pathogenesis of SLE. J Exp Med 205: 3007-3018. doi:10.1084/jem.20081165. PubMed: 19064698.
42. Sims GP, Rowe DC, Rietdijk ST, Herbst R, Coyle AJ, (2010) HMGB1 and RAGE in inflammation and cancer. Annu Rev Immunol 28: 367-388. doi:10.1146/annurev.immunol.021908.132603. PubMed: 20192808.
43. Huang B, Sikorski R, Kirn DH, Thorne SH, (2011) Synergistic anti-tumor effects between oncolytic vaccinia virus and paclitaxel are mediated by the IFN response and HMGB1. Gene Therapy 18: 164-172. doi:10.1038/gt.2010.121. PubMed: 20739958.
44. Lousberg EL, Diener KR, Brown MP, Hayball JD, (2011) Innate immune recognition of poxviral vaccine vectors. Expert Rev Vaccines 10: 1435-1449. doi:10.1586/erv.11.121. PubMed: 21988308.
45. Kim JW, Gulley JL, (2012) Poxviral vectors for cancer immunotherapy. Expert Opin Biol Ther 12: 463-478. doi:10.1517/14712598.2012.668516. PubMed: 22413824.
46. Dye C, Fine PE, (2013) A major event for new tuberculosis vaccines. Lancet 6736: 3-5. doi:10.1016/S0140-6736(13)60137-3.
47. Kastenmuller W, Drexler I, Ludwig H, Erfle V, Peschel C, et al. (2006) Infection of human dendritic cells with recombinant vaccinia virus MVA reveals general persistence of viral early transcription but distinct maturation-dependent cytopathogenicity. Virology 350: 276-288. doi:10.1016/j.virol.2006.02.039. PubMed: 16595141.
48. Nájera JL, Gómez CE, Domingo-Gil E, Gherardi MM, Esteban M, (2006) Cellular and biochemical differences between two attenuated poxvirus vaccine candidates (MVA and NYVAC) and role of the C7L gene. J Virol 80: 6033-6047. doi:10.1128/JVI.02108-05. PubMed: 16731942.
49. Alexopoulou L, Thomas V, Schnare M, Lobet Y, Anguita J, et al. (2002) Hyporesponsiveness to vaccination with Borrelia burgdorferi OspA in humans and in TLR1- and TLR2-deficient mice. Nat Med 8: 878-884. doi:10.1038/nm732. PubMed: 12091878.
50. Fletcher H, Whelan KT, Alder NC, Sander CR, Hill AVS, (2008) Boosting BCG vaccination with MVA85A down-regulates the immunoregulatory cytokine TGF-β1. 26: 5269-5275.
51. Guerra S, González JM, Climent N, Reyburn H, López-Fernández, La et al (2010) Selective induction of host genes by MVA-B, a candidate vaccine against HIV/AIDS. J Virol 84: 8141-8152. doi:10.1128/JVI.00749-10. PubMed: 20534857.
52. Zhu J, Martinez J, Huang X, Yang Y, (2007) Innate immunity against vaccinia virus is mediated by TLR2 and requires TLR-independent production of IFN-beta. Blood 109: 619-625. doi:10.1182/blood-2006-06-027136. PubMed: 16973959.
53. Erridge C, (2010) Endogenous ligands of TLR2 and TLR4: agonists or assistants? J Leukoc Biol 87: 989-999. doi:10.1189/jlb.1209775. PubMed: 20179153.
54. McFadden G, (2005) Poxvirus tropism. Nat Rev Microbiol 3: 201-213. doi:10.1038/nrmicro1099. PubMed: 15738948.
55. Griffiths KL, Pathan, A a, Minassian AM, Sander CR, Beveridge NER,et al (2011) Th1/Th17 cell induction and corresponding reduction in ATP consumption following vaccination with the novel Mycobacterium tuberculosis vaccine MVA85A. PLOS ONE 6: e23463. doi:10.1371/journal.pone.0023463. PubMed: 21887254.
56. Bell CW, Jiang W, Reich CF, Pisetsky DS, (2006) The extracellular release of HMGB1 during apoptotic cell death. Am J Physiol Cell Physiol 291: C1318-C1325. doi:10.1152/ajpcell.00616.2005. PubMed: 16855214.
57. Betts G, Poyntz H, Stylianou E, Reyes-Sandoval A, Cottingham M, et al. (2012) Optimising immunogenicity with viral vectors: mixing MVA and HAdV-5 expressing the mycobacterial antigen Ag85A in a single injection. PLOS ONE 7: e50447. doi:10.1371/journal.pone.0050447. PubMed: 23284637.
58. R Development Core Team (2011) R: A language and environment for statistical computing. Vienna, Austria.
59. Smyth GK, (2005) Limma: linear models for microarray data. In: Gentleman R, Carey V, Dudoit S, Irizarry R, Huber W,. Bioinformatics and Computational Biology Solutions using R and Bioconductor. New York: Springer Verlag. pp. pp. 397-420.
60. Ritchie ME, Diyagama D, Neilson J, Van Laar R, Dobrovic A, et al. (2006) Empirical array quality weights in the analysis of microarray data. BMC Bioinformatics 7: 261. doi:10.1186/1471-2105-7-261. PubMed: 16712727.
61. Shi W, Oshlack A, Smyth GK, (2010) Optimizing the noise versus bias trade-off for Illumina whole genome expression BeadChips. Nucleic Acids Res 38: e204. doi:10.1093/nar/gkq871. PubMed: 20929874.